Sapogenins Glycosides Clinical Trials

Size	Price	Qty
10mg	USD 380

Clinical Trials

A completed clinical trial sponsored by an academic institution, North Carolina Agriculture & Technical State University, investigated the bioavailability of oat bran saponins alongside key parameters in pharmacokinetics and polyphenols. Classified under a phase of not applicable, this research highlights that clinical evaluation of these sapogenin glycosides remains centered on nutritional pharmacokinetic profiling and metabolic disposition rather than late-stage interventional disease indications.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04335435	Completed	Human Health\|Polyphenols\|Pharmacokinetics	North Carolina Agriculture & Technical State University	2016-01-15	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Sapogenins Glycosides product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Sapogenins glycosides interact with membrane sterols and vascular tissue targets, inhibiting inflammatory signaling cascades and reducing vascular permeability. This restored endothelial integrity and suppressed tissue inflammation underlie their clinical relevance in human health and pharmacokinetic bioavailability studies, as well as their therapeutic potential in addressing venous insufficiency.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).